Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

ConditionKidney Transplant; Complications

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorShahid Beheshti University of Medical Sciences

About this trial

Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).

Eligibility criteria

Qualifiers

All Kidney transplant recipients

Disqualifiers

Kidney-Pancreas transplant BMI>30 cPRA>0%

Trial design

Treatments tested in this trial

Rapamune Pill

Treatment groups

50 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Shahid Beheshti University of Medical Sciences

Lead sponsor

Source ClinicalTrials.gov